Incidence and predictors for late target lesion revascularization after sirolimus-eluting stent implantation

Circ J. 2013;77(4):988-94. doi: 10.1253/circj.cj-12-0570. Epub 2012 Dec 28.

Abstract

Background: In long-term follow-up after drug-eluting stents (DES) implantation, late target lesion revascularization (TLR) is occasionally required. However, the incidence and predictors for late TLR with DES have not been fully investigated.

Methods and results: Between August 2004 and March 2005, 249 consecutive patients underwent percutaneous coronary intervention with sirolimus-eluting stents (SES) at our institution. Angiographic follow-up data were obtained in 228 patients (91.6%) with 274 lesions (91.6%) at 8 months. TLR incidence was evaluated up to 5 years. The 5-year clinical follow-up data were obtained in 222 patients (97.4%) with 264 lesions (96.4%). The incidence of early TLR before 1 year was 16.7%, and that of late TLR (1-5 years) was 8.3% (2.1% per year). Multivariate analysis indicated that significant predictors for late TLR were insulin-treated diabetes mellitus (DM) (odds ratio (OR) 10.88, P=0.001), stent fracture (OR 27.24, P=0.012), and age (OR 0.94, P=0.026). No association was observed between late TLR and lesion characteristics, including parameters measured by quantitative coronary angiography other than stent fracture, at baseline, post procedure, and follow-up.

Conclusions: Late TLR after SES implantation occurred in approximately 2.1% of lesions per year after the first year without attenuation up to 5 years. Significant predictors for late TLR were insulin-treated DM, stent fracture and younger age. Careful long-term follow-up after SES implantation might be recommended.

Publication types

  • Clinical Trial

MeSH terms

  • Age Factors
  • Aged
  • Antibiotics, Antineoplastic / pharmacology*
  • Coronary Angiography
  • Diabetes Mellitus / drug therapy
  • Drug-Eluting Stents / adverse effects*
  • Female
  • Follow-Up Studies
  • Graft Occlusion, Vascular / diagnostic imaging
  • Graft Occlusion, Vascular / epidemiology*
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Incidence
  • Insulin / administration & dosage
  • Insulin / adverse effects
  • Male
  • Middle Aged
  • Prosthesis Failure / adverse effects
  • Risk Factors
  • Sirolimus / pharmacology*

Substances

  • Antibiotics, Antineoplastic
  • Hypoglycemic Agents
  • Insulin
  • Sirolimus